Creative Planning Acquires New Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

Creative Planning acquired a new stake in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 22,136 shares of the company’s stock, valued at approximately $76,000.

A number of other institutional investors have also modified their holdings of the business. Optimum Investment Advisors bought a new stake in Mind Medicine (MindMed) in the second quarter worth about $28,000. Clear Street Markets LLC bought a new stake in Mind Medicine (MindMed) in the second quarter worth about $35,000. Fulton Breakefield Broenniman LLC bought a new stake in Mind Medicine (MindMed) in the second quarter worth about $37,000. IFP Advisors Inc bought a new stake in Mind Medicine (MindMed) in the second quarter worth about $42,000. Finally, Invst LLC bought a new stake in Mind Medicine (MindMed) in the second quarter worth about $51,000. Hedge funds and other institutional investors own 12.18% of the company’s stock.

Several brokerages have commented on MNMD. Maxim Group began coverage on shares of Mind Medicine (MindMed) in a research report on Monday, June 28th. They issued a “buy” rating and a $6.00 price target on the stock. Canaccord Genuity dropped their price target on shares of Mind Medicine (MindMed) from C$5.00 to C$4.25 and set a “buy” rating on the stock in a research report on Wednesday, August 18th. Finally, HC Wainwright initiated coverage on Mind Medicine (MindMed) in a research note on Thursday, August 5th. They issued a “buy” rating and a $10.00 price target on the stock.

Shares of MNMD opened at 2.29 on Wednesday. The business has a 50-day moving average of 2.96. The stock has a market cap of $702.31 million and a PE ratio of -13.47. Mind Medicine has a 1-year low of 0.33 and a 1-year high of 5.77.

Mind Medicine (MindMed) (NASDAQ:MNMD) last issued its quarterly earnings results on Thursday, August 12th. The company reported -0.09 earnings per share for the quarter, missing the Zacks’ consensus estimate of -0.04 by -0.05. Analysts expect that Mind Medicine will post -0.19 EPS for the current fiscal year.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed), Inc operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L.

Recommended Story: Learning About the VIX – Volatility Index

Institutional Ownership by Quarter for Mind Medicine (MindMed) (NASDAQ:MNMD)

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.